The lack of interest has always been Orthocells number one...

The lack of interest has always been Orthocells number one problem. We have seen an increase from 33 cents to a now 40 cents, through a couple of big buys, we are starting to see cash flow positive quarters.

Management are keeping there cards close to their chests about pricing per individual Striate+ sales, like most, I know this price will change when buying in bulk, we are able to produce 100k per year, it shouldn’t take long before a new facility will be needed to produce half a million per year. Throw in

Remplir, FDA approval, partnership,

ATI results, FDA approval, partnership

ACL (Rope) larger animal study results maybe this year, approvals, partnerships

Investors and brokers will start to take notice, unfortunately until then, Orthocell is a small cap our share price is owned by small retail, who are happy to make 5% profits on a 10k hold

Back in the day Port Phillip Publishing recommended to there subscribers OCC was a buy, our share price went berserk with up to 1000 trades per day, 10- 15 million shares trading hands on announcement days, 38 cent at that time to 99 cents the highest our share price had ever been, investors made up to 130% profits

So here we are now, Striate+ Global partnership, another partnership in the wind, cash flow positive, Remplir, ATI and ACL results out very soon, partnerships to follow, and our share price is lucky to hold over 40 cents.